`
`AO 1260 (Rev. 08/10) To:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`2.0. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`__
`
`1° 92-€V-23,
`
`in Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § L116 you are hereby advised that a court action has been
`filed in the U.S. District Court
`for the Northern District of West Virginia
`on the following
`(}Trademarks or
`Patents.
`the patent action involves 35 U.S.C. § 292.}:
`
`[7]
`
`(
`
`DOCKET NO.
`
`iDATE FILED
`3/18/2022
`
`PLAINTIFF
`NOVO NORDISK INC. and NOVO NORDISK A/S
`
`NUS. DISTRICT COURT
`for the Northern District of West Virginia
`DEFENDANT _
`| MYLAN PHARMACEUTICALS INC.
`
`jnnannnncen
`
`
`7
`as
`DATE OF PATENT
`PATENT OR
`HOLDER OF PATENT OR TRADEMARK
`—_
`OR TRADEMARK
`TRADEMARK NO.
`
`
`
`Novo Nordisk A/S
`2114/2012
`{ 8,714,833
`|
`
`
`
`
`
`
`HE2042
`
`
`
`
`9/17/2013
`
`
`saots
`
`Novo Nordisk A/S
`
`Novo Nordisk A/S
`
`Novo Nordisk A/S
`
`2 8,129,343
`
`COANE
`
`3 8,536,122
`(4 8,684,969
`(ene
`5 8,920,383
`
`
`
`42/30/2014
`
`
`
` Novo Nordisk A/S
`
`DATE INCLUDED
`
`in the above—-entitled case, the following patent(s¥ trademark(s) have been inchided:
`INCLUDED BY
`
`ii Answer
`
`C] Cross Bil
`
`["] Other Pleading
`
`C7} Amendment
` DATEOF PATENT
`PATENTOR |
`TRADEMARK
`TRADEMARK NO,
`__
`i ___ OR
`
`
`HOLDER GF PATENT OR TRADEMARK
`DECISIONJUDGEMENT
`
`AANAARAN
`
`
`CLERK
`CHERYL BEAN RILEY
`
`CUOOLAAARALRARARALOUUUDSLIAAIONAAUARAAoR KAAASISAAVccNANTISNAINAII\ANAICNAAANANANANANARAAASIAD
`__L_3/8/2022
`
`
`
`(BY) DEPUTY CLERK
`
` D. KINSEY
`
`[DATE
`
`Copy 1—Upon initiation of action, mail this capy to Director Copy 3—Upan termination of action, mail this capy to Director
`Copy 2-—Upon filing decument adding patent(s}, mail this copy to Director Copy 4—Case fe copy
`
`
`
`Case L:22-cv-00023-IMEK Document? Filed O3/is/e2 Page 2af2 PagelD455
`
`P DOCKET NO.
`
`| PLAINTIFF
`
`| DATE FILED
`
`3/18/2022
`
`US. DISTRICT COURT
`_
`for the Northern District of West Virginia
`OEFENDANT
`
`NOVO NORDISEINC, and
`NOVO NORDISK A/S
`
`HOLDER OF PATENT OR TRADEMARK
`
`MYLAN PHARMACEUTICALS INC.
`Novo Nordisk A/S Nove Nordisk A/S
`OR TRADEMARK
`
`1/09/2018
`:
`9,861,757
`(Sjos2019
`10,220,155
`
`13|10,335,462 F0U2019 Novo Nordisk A/S
`3| 10,357,616
`THI3/2019
`
`6|10,376,652 8/13/2019
`Nove Nordisk A/S
`
`17|11,097,063 8/24/2021
`Nove Nordisk A/S
`(8) REA6,363
`af 72617
`Novo Nordisk A/S
`_
`—
`Cs
`
`DATE OF PATENT
`PATENT OR
`OR TRADEMARE
`TRADEMARK NO.
`| Novo Nordisk A/S
`8/18/2015
`|
`| 9,108,002
`s
`
`[7|9332239| OTS2615
`| Novo Nordisk A/S
`| Novo Nordisk A/S
`Novo Nordisk A/S
`Novo Nonds S
`Novo Nordisk ASS
`| Novo Nordisk AIS
`
`10/04/2016
`
`2fasi6is0| ana0n7
`pe)9,687,611)
`aon
`9,775,953
`10/03/2017
`
`~
`
`
`
`
`
`DATE INCLUDED
`
`PATENT OR
`TRADEMARK NO.
`
`In the above-—entitled case, the following patent(s¥ trademark(s) have been included:
`
`INCLUDED BY
`Amendment
`
`DATE OF PATENT
`
`r Answer
`
`Pp] Cross Bill | Other Pleading
`
`